MDM2 and MDMX in cancer and development.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current Topics in Developmental Biology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/B978-0-12-380916-2.00003-6PMID 21295684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo

  2010cited by this paper
• An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.

  2010cited by this paper
• p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation

  2010cited by this paper
• p53 polymorphisms: cancer implications

  2009cited by this paper
• RYBP stabilizes p53 by modulating MDM2

  2009cited by this paper
• NUMB controls p53 tumour suppressor activity

  2008cited by this paper
• Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites

  2008cited by this paper
• The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss.

  2008cited by this paper
• Recurrent initiation: a mechanism for triggering p53 pulses in response to DNA damage.

  2008cited by this paper
• Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2

  2008cited by this paper
• Unlocking the Mdm2-p53 loop: Ubiquitin is the key

  2008cited by this paper
• Cooperation between the ribosomal proteins L5 and L11 in the p53 pathway

  2008cited by this paper
• SUMO-Specific Protease 2 Is Essential for Modulating p53-Mdm2 in Development of Trophoblast Stem Cell Niches and Lineages

  2008cited by this paper
• Restoration of p53 function leads to tumour regression in vivo

  2007cited by this paper
• Putting a Finger on Growth Surveillance: Insight into MDM2 Zinc Finger-Ribosomal Protein Interactions

  2007cited by this paper
• The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop.

  2007cited by this paper
• MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis.

  2007cited by this paper
• Haploinsufficiency of Mdm2 and Mdm4 in Tumorigenesis and Development

  2007cited by this paper
• Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

  2007cited by this paper
• Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers

  2007cited by this paper
• Mdm2 targets the p53 transcription cofactor JMY for degradation

  2007cited by this paper
• MDMX: from bench to bedside

  2007cited by this paper
• Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2

  2007cited by this paper
• Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo.

  2006cited by this paper
• Modeling the therapeutic efficacy of p53 restoration in tumors.

  2006cited by this paper
• 14‐3‐3γ binds to MDMX that is phosphorylated by UV‐activated Chk1, resulting in p53 activation

  2006cited by this paper
• Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage

  2006cited by this paper
• The first knockout mouse model of retinoblastoma.

  2006cited by this paper
• p53 ubiquitination: Mdm2 and beyond.

  2006cited by this paper
• A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

  2006cited by this paper
• Tissue-Specific Differences of p53 Inhibition by Mdm2 and Mdm4

  2006cited by this paper
• Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

  2006cited by this paper
• Regulation of MDMX nuclear import and degradation by Chk2 and 14‐3‐3

  2006cited by this paper
• Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

  2006cited by this paper
• Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo

  2006cited by this paper
• Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence

  2006cited by this paper
• Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4

  2006cited by this paper
• Divorcing ARF and p53: an unsettled case

  2006cited by this paper
• Translational research? Ribosome integrity and a new p53 tumor suppressor checkpoint

  2006cited by this paper
• Inactivation of the p53 pathway in retinoblastoma

  2006cited by this paper
• Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death

  2006cited by this paper
• Tumor suppression and normal aging in mice with constitutively high p53 activity.

  2006cited by this paper
• Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3.

  2006cited by this paper
• ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

  2005cited by this paper
• Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.

  2005cited by this paper
• Mdmx as an essential regulator of p53 activity.

  2005cited by this paper
• Use of Preclinical Models to Improve Treatment of Retinoblastoma

  2005cited by this paper
• hnRNP K: an HDM2 target and transcriptional coactivator of p53 in response to DNA damage.

  2005cited by this paper
• Phosphorylation of MdmX by CDK2/Cdc2p34 is required for nuclear export of Mdm2

  2005cited by this paper
• Death squads enlisted by the tumour suppressor p53.

  2005cited by this paper
• Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.

  2005cited by this paper
• Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.

  2005cited by this paper
• Phosphorylation of MdmX by CDK2/Cdc2p34 is required for nuclear export of Mdm2

  2005cited by this paper
• Rescue of Mdm4-deficient mice by Mdm2 reveals functional overlap of Mdm2 and Mdm4 in development

  2005cited by this paper
• Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.

  2005cited by this paper
• ATM and Chk2‐dependent phosphorylation of MDMX contribute to p53 activation after DNA damage

  2005cited by this paper
• G1 checkpoint failure and increased tumor susceptibility in mice lacking the novel p53 target Ptprv

  2005cited by this paper
• Significance of HDMX‐S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis

  2005cited by this paper
• DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation

  2005cited by this paper
• The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality

  2005cited by this paper
• Modification of MDMX by sumoylation.

  2005cited by this paper
• Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

  2004cited by this paper
• Accelerated MDM2 auto‐degradation induced by DNA‐damage kinases is required for p53 activation

  2004cited by this paper
• Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity.

  2004cited by this paper
• The ubiquitin ligase COP1 is a critical negative regulator of p53

  2004cited by this paper
• Tumour suppression: Disruption of HAUSP gene stabilizes p53

  2004cited by this paper
• Asymmetric cell division.

  2004cited by this paper
• In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

  2004cited by this paper
• Yin Yang 1 is a negative regulator of p53.

  2004cited by this paper
• A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.

  2004cited by this paper
• MDM2 and its splice variant messenger RNAs: expression in tumors and down-regulation using antisense oligonucleotides.

  2004cited by this paper
• Mdmx and Mdm2: Brothers in Arms?

  2004cited by this paper
• Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity

  2004cited by this paper
• Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics.

  2004cited by this paper
• PML regulates p53 stability by sequestering Mdm2 to the nucleolus

  2004cited by this paper
• A dynamic role of HAUSP in the p53-Mdm2 pathway.

  2004cited by this paper
• Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation.

  2004cited by this paper
• The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression.

  2004cited by this paper
• Inhibition of p53 degradation by Mdm2 acetylation

  2004cited by this paper
• The First Knockout Mouse Model of Retinoblastoma

  2004cited by this paper
• MDM2 Promotes Ubiquitination and Degradation of MDMX

  2003cited by this paper
• p53-independent functions of MDM2.

  2003cited by this paper
• Mdm2 haplo‐insufficiency profoundly inhibits Myc‐induced lymphomagenesis

  2003cited by this paper
• Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300

  2003cited by this paper
• Mono- Versus Polyubiquitination: Differential Control of p53 Fate by Mdm2

  2003cited by this paper
• Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target

  2003cited by this paper
• Posttranslational modification of MDM2.

  2003cited by this paper
• mdm2 Is Critical for Inhibition of p53 during Lymphopoiesis and the Response to Ionizing Irradiation

  2003cited by this paper
• Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation

  2003cited by this paper
• Oxygen sensitivity severely limits the replicative lifespan of murine fibroblasts

  2003cited by this paper
• Hdmx Protein Stability Is Regulated by the Ubiquitin Ligase Activity of Mdm2*

  2003cited by this paper
• Identification of a domain within MDMX‐S that is responsible for its high affinity interaction with p53 and high‐level expression in mammalian cells

  2003cited by this paper
• DNA Damage-induced MDMX Degradation Is Mediated by MDM2*

  2003cited by this paper
• HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53

  2003cited by this paper
• Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.

  2003cited by this paper
• Mammalian Numb is a target protein of Mdm2, ubiquitin ligase.

  2003cited by this paper
• Physical and Functional Interactions between PML and MDM2*

  2003cited by this paper
• Hdmx Recruitment into the Nucleus by Hdm2 Is Essential for Its Ability to Regulate p53 Stability and Transactivation*

  2002cited by this paper
• The RB and p53 pathways in cancer.

  2002cited by this paper
• Zebrafish as a model organism for the identification and characterization of drugs and genes affecting p53 signaling.

  2002cited by this paper

• The Association and Significance of MDM2 and NF-κB Protein Expression in Multiple Myeloma

  2025cites this paper
• Molecular Mechanism of P53 Peptide Permeation through Lipid Membranes from Solid-State NMR Spectroscopy and Molecular Dynamics Simulations.

  2024cites this paper
• Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance

  2024cites this paper
• Upregulation of YPEL3 expression and induction of human breast cancer cell death by microRNAs

  2024cites this paper
• The Development of p53-Targeted Therapies for Human Cancers

  2023cites this paper
• MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity

  2022cites this paper
• Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment

  2021cites this paper
• Associations of MDM2 and MDM4 Polymorphisms with Early-Stage Breast Cancer

  2021cites this paper
• Binding Ensembles of p53-MDM2 Peptide Inhibitors by Combining Bayesian Inference and Atomistic Simulations

  2021cites this paper
• Computational modeling of cyclic peptide inhibitor–MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations

  2020cites this paper
• Spatial profiling of stapled α–helical peptide ATSP-7041 in mouse whole-body thin tissue sections using droplet-based liquid microjunction surface sampling-HPLC-ESI–MS/MS

  2019cites this paper
• Inhibition of p53 inhibitors: progress, challenges and perspectives

  2019cites this paper
• Improving cancer therapy with new p53-activating agents

  2019cites this paper
• Glycyrrhiza polysaccharide protects GES-1 cells from ethyl alcohol induced injury through Akt-Mdm 2p 53 signal pathway

  2018cites this paper
• Genetics, prognosis, and transplantation for myelofibrosis

  2018cites this paper
• Bioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancer

  2017cites this paper
• Sheet 1 of 10 US 9 . 408 , 885 B 2 Primary Melanoma c Regional Dermal

  2017cites this paper
• Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation.

  2017cites this paper
• Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

  2017cites this paper
• Macrocycles for protein–protein interactions

  2017cites this paper
• E3 ubiquitin ligases in cancer and implications for therapies

  2017cites this paper
• d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.

  2017cites this paper
• Molecular chaperones in the acquisition of cancer cell chemoresistance with mutated TP53 and MDM2 up-regulation

  2017cites this paper
• Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth.

  2016cites this paper
• Bridged Analogues for p53-Dependent Cancer Therapy Obtained by S-Alkylation

  2016cites this paper
• RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.

  2016cites this paper
• Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB

  2016cites this paper
• Pharmacological reactivation of p53 as a strategy to treat cancer

  2015cites this paper
• Targeting Mdmx to treat breast cancers with wild-type p53

  2015cites this paper
• E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.

  2015cites this paper
• Wild type p53 reactivation: From lab bench to clinic

  2014cites this paper
• Mdm2 and MdmX involvement in human cancer.

  2014cites this paper
• Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity

  2014cites this paper
• The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

  2014cites this paper
• Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival

  2014cites this paper
• Stapled α−helical peptide drug development: A potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy

  2013cites this paper
• Genetic variants in p53-related genes confer susceptibility to second primary malignancy in patients with index squamous cell carcinoma of head and neck.

  2013cites this paper
• The Role of an Oncoprotein CIP2A in Breast Cancer

  2013cites this paper
• Molecular Pathways Molecular Pathways : Targeting Mdm 2 and Mdm 4 in Cancer Therapy

  2012cites this paper
• Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.

  2012cites this paper
• MDM4 is a key therapeutic target in cutaneous melanoma

  2012cites this paper
• Dual Roles of MDM2 in the Regulation of p53: Ubiquitination Dependent and Ubiquitination Independent Mechanisms of MDM2 Repression of p53 Activity.

  2012cites this paper
• Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells.

  2012cites this paper